CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Samsrita Labs Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Samsrita Labs Ltd
6-3-354/13/B2, Flat.No.B2
Suryateja Apartments,, Hindi Nagar, Punj
Phone: +91 2228520461p:+91 2228520461 HYDERABAD, 500082  India Ticker: 539267539267
Business Summary
Samsrita Labs Ltd is an India-based biopharma company. The Company is engaged activities, such as trading, exports and imports, manufacturing of bulk drugs, APIs, Specialty drugs, research and development (R&D) through joint ventures or associations or mergers or by its own. It has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
8071 Medical laboratories
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Kalidindi K.Raju 58 8/30/2019
Chief Financial Officer K. N. V. N.Kumar 2/14/2020 2/14/2020
Non-Executive Director Mohammed A.Habeeb 50
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 14,808,706 (As of 9/30/2023)
Stock Exchange: BOM
Fax Number: +91 2228511809


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024